Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Chemomab Therapeutics Ltd. Director's Dealing 2021

Mar 12, 2021

35107_dirs_2021-03-12_0801f451-ddd9-4b5c-87cd-3837d31083b7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Anchiano Therapeutics Ltd. (ANCN)
CIK: 0001534248
Period of Report: 2020-04-23

Reporting Person: Polovets Stanislav (Director)

More from Chemomab Therapeutics Ltd.

Board/Management Information 2026
Jun 2
Report Publication Announcement 2026
May 14
Regulatory Filings 2026
Mar 19
Regulatory Filings 2025
Nov 21
Capital/Financing Update 2025
Aug 22
Interim / Quarterly Report 2025
Aug 14
Major Shareholding Notification 2025
Aug 11
Capital/Financing Update 2025
Jul 25
Capital/Financing Update 2025
Jul 25
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 1
View all filings →